Navigation Links
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Date:4/2/2009

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the expected timing of the start of clinical trials with MT203, and the potential uses of MT203 and our other product candidates. You are urged to consider statements that include the words "looking forward," "ongoing," "may," "will," "believes," "potential," "expected," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ende
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package.  This three-in-one device allows ... in their designs - cutting installation time by ...
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... , June 18, 2013  It has ... of Alliance Seating and Mobility, a subsidiary company ... access timely repair. This appears to be due ... reduction of field service employees.  ... great many of these clients are complex mobility ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
... 21, 2010 Takeda Pharmaceutical Company Limited ("Takeda") ... Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed ... against the companies in response to their Abbreviated ... HCl), ACTO plus met® (pioglitazone HCl and ...
... Dec. 21, 2010 Today, Pepex Biomedical, Inc. announced ... $244,479.25 under the Qualifying Therapeutic Discovery Project created by ... Affordable Care Act of 2010, the major health care ... March 23, 2010.  Pepex submitted their ground-breaking, patented, electrochemical ...
Cached Medicine Technology:Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6Pepex™ Awarded Qualifying Therapeutic Discovery Project Grant 2
(Date:6/18/2013)... Palo Alto has taken yet another step in ... its recent major long-term solar power commitment. , Last ... power purchase agreements , which together will result in the ... electric power per year, which is the equivalent of roughly ... power to supply all 65,000+ Palo Alto residents---and then some! ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... M2a Magnum hip continue to move forward in a ... Indiana, Bernstein Liebhard LLP reports. According to court ... on June 17th, at which time the Court also ... scientific and technical issues pertinent to the Biomet hip ...
(Date:6/18/2013)... June 18, 2013 Sun Buick GMC, Moosic, ... Health Services 20th Annual Golf Tournament on Thursday, June 20, ... hole-in-one prize is a 2013 Buick Verano and will go ... a hole-in-one on Irem’s 7th hole. , The MFHS golf ... is a four person captain and crew team for 18 ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... 18, 2013 Internationally acclaimed plastic ... website, thebestbreast.com, showcasing his unique approach to breast ... about his surgical method and highlights the results ... his website, Dr. Tebbetts compares his breast augmentation ... Dr. Tebbetts’ method does not necessitate the use ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2
... M. Miano, Ph.D associate professor within the Cardiovascular Research ... that // small regulatory DNA sequences control ... scanned the vast human DNA code to reveal 60 ... of the study were published in the journal Genome ...
... one of the National Institutes of Health has awarded ... Infectious Disease Agent Study (MIDAS) grants to // ... research team. , The goal of this ... techniques. These techniques would be used later to quickly ...
... treatment benefits with your doctor does not seems to benefit ... Colleagues, University of California, San Francisco found in a study ... and shared the decision with their doctor. ,The ... patient did not benefit the patient in deciding the symptoms ...
... has revealed that investing more money in the country’s healthcare ... necessarily// result in better services. The manner in which the ... the author of the report. The name of the report ... healthcare system in the country is available at British Columbia, ...
... for rotavirus has been approved by the US. The rotavirus ... of about 500,000 children across the world annually. // In ... medicine's maker tested the vaccine on more than 70,000 children ... ,Rotavirus is a highly contagious virus that causes severe dehydrating ...
... will be recruiting Indian nurses to overcome the shortage of ... Nursing at Medi-Clinic, told the Afrikaans daily Beeld here that ... for India to start a selection process for 60 clinical ... project in the Western Cape Province, where the shortage of ...
Cached Medicine News:Health News:Human Complexity Can Be Attributed To Regulatory Sequence 2Health News:Detecting Epidemics using statistics 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: